RCS - Envision Pharma Grp - Envision Pharma Group Announcement
Wed 14:00
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260408:nRSH5153Za&default-theme=true
RNS Number : 5153Z Envision Pharma Group 08 April 2026
Envision Pharma Group appoints Nick Jones as President, Envision Medical
Communications
Seasoned technology and life sciences leader to advance AI integration across
medical communications
FAIRFIELD, CT / ACCESS Newswire / April 8, 2026 / Envision Pharma Group
(Envision), a global, technology-enabled solutions partner to the life
sciences industry, today announced the appointment of Nick Jones as President,
Envision Medical Communications (EMC). In this role, Jones will lead the EMC
business, focusing on integrating Envision's industry-leading technology and
AI capabilities into its award-winning portfolio of solutions and services.
Jones joins the company from ConcertAI, where he served as Senior Vice
President and General Manager, Commercial Solutions, leading teams delivering
consulting services, AI-driven software-as-a-service solutions, and data
products supporting pharmaceutical commercialization.
Prior to ConcertAI, he spent over a decade at IQVIA (formerly IMS), leading
technology and consulting organizations across the US, Europe, and JAPAC,
delivering an integrated solutions portfolio spanning technology, consulting,
real-world evidence, and analytics to global and mid-size pharma clients.
Jones will report directly to Tom Langan, CEO of Envision Pharma Group, and
join Envision's Executive Leadership Team.
"Nick brings deep expertise, global market insight, and a shared ambition to
build a world-class, tech-enabled pharma services organization," says Langan.
"His broad experience in technology and consulting will benefit both Envision
and our clients. This is yet another step in our evolution as we strive to
execute with precision and exceed client expectations."
Jones adds, "Envision has consistently stood out in the pharma services
industry for its credibility and excellence in medcomms. I am excited to join
the company, and EMC in particular, as we build a market-leading, tech-enabled
portfolio to meet the evolving needs of our pharma clients."
-Ends-
About Envision Pharma Group
Envision Pharma Group is a global, technology-enabled solutions partner to the
life sciences industry. We harness the power of combined intelligence -human
expertise and technology - to advance how scientific innovation translates
into improved patient outcomes. We unite scientific expertise, strategic
insight, and AI-powered tools to help clients create, communicate, and
demonstrate value, accelerating access to life-changing treatments. With more
than 20 years of experience and trusted partnerships with 400+ biopharma
companies, including all top 20 pharma, we deliver integrated solutions across
the product lifecycle, from medical communications to commercialization and
compliance, through flexible models that scale to client needs. Together, we
combine human insight and technology to drive smarter decisions, measurable
impact, and sustainable growth.
Learn more: www.envisionpharmagroup.com (https://pr.report/kgnl)
For more information, contact:
Sophie Berger, Global Head, Marketing, Envision Pharma Group
Email: sophie.berger@envisionpharma.com
Brittany Bowen, Media Relations, Geben Communication
Email: brittanybowen@gebencommunication.com
SOURCE: Envision Pharma Group
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NRASSUFLWEMSEDL
Copyright 2019 Regulatory News Service, all rights reserved